Nuvilex COO Highlights Advantages and Applications of Platform Cell Encapsulation Technology for Cancer, Diabetes, and Stem Cells During Recent Interview With

Published: Dec 18, 2012

SILVER SPRING, Md., Dec. 18, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today that major aspects of its core, "platform," cell encapsulation technology were discussed recently by Nuvilex's COO, Dr. Gerald W. Crabtree, during an interview with Advantages of Nuvilex's cell encapsulation technology, as well as its possible applications in the development of treatments for serious, debilitating, and even fatal diseases were emphasized.

Back to news